Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck - A Hellenic cooperative oncology group phase II study
dc.contributor.author | Fountzilas, G. | en |
dc.contributor.author | Tolis, C. | en |
dc.contributor.author | Kalogera-Fountzila, A. | en |
dc.contributor.author | Misailidou, D. | en |
dc.contributor.author | Tsekeris, P. | en |
dc.contributor.author | Karina, M. | en |
dc.contributor.author | Nikolaou, A. | en |
dc.contributor.author | Samantas, E. | en |
dc.contributor.author | Makatsoris, T. | en |
dc.contributor.author | Athanassiou, E. | en |
dc.contributor.author | Skarlos, D. | en |
dc.contributor.author | Bamias, A. | en |
dc.contributor.author | Zamboglou, N. | en |
dc.contributor.author | Economopoulos, T. | en |
dc.contributor.author | Karanastassi, S. | en |
dc.contributor.author | Pavlidis, N. | en |
dc.contributor.author | Daniilidis, J. | en |
dc.date.accessioned | 2015-11-24T18:39:16Z | |
dc.date.available | 2015-11-24T18:39:16Z | |
dc.identifier.issn | 1357-0560 | - |
dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/17413 | |
dc.rights | Default Licence | - |
dc.subject | paclitaxel | en |
dc.subject | chemotherapy | en |
dc.subject | head and neck cancer | en |
dc.subject | induction chemotherapy | en |
dc.subject | radiation-therapy | en |
dc.subject | randomized-trial | en |
dc.subject | organ preservation | en |
dc.subject | weekly carboplatin | en |
dc.subject | cancer | en |
dc.subject | radiotherapy | en |
dc.subject | survival | en |
dc.subject | radiochemotherapy | en |
dc.subject | oxaliplatin | en |
dc.title | Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck - A Hellenic cooperative oncology group phase II study | en |
heal.abstract | The primary objective of this phase II study was to access the complete response (CR) rate to a new innovative induction regimen in patients with locally advanced head and neck cancer (LA-HNC). From October 2000 until October 2003 a total of 38 eligible patients (33 men and 5 women) entered the study. The large majority of them presented with a performance status of 0-1 and with clinical stage IV disease. Treatment consisted of three cycles of induction chemotherapy (IC) with paclitaxel 175 mg/m(2) in a 3-h infusion on d 1, leucovorin (LV) 200 mg/m(2) over 20 min immediately followed by FU 400 mg/m(2) bolus and then 600 mg/m(2) as a 24-h continuous infusion on d 1 and 2 and a cisplatin 75 mg/m(2) over 1-h infusion on d 2 every 3 wk. This was then followed by radiation (70 Gy) and weekly cisplatin 40 mg/m(2). After the completion of IC, 6/38 (16%) patients had CR. The CR rate was increased to 66% post-concomitant chemoradiotherapy (CCRT). Neutropenia (37.5%), pain (62%), nausea/vomiting (21%), and alopecia (79%) were the most frequent side effects during IC. The most pronounced toxicities during chemoradiotherapy were stomatitis (62.5%) and xerostomia (53%). Median time to progression was 11.0 mo and median survival 16.7 mo. One- and 2-yr survival rates were 73% and 38%, respectively. In conclusion, this novel induction regimen is active, is well tolerated, and can be successfully followed by CCRT with weekly cisplatin. CCRT should remain standard treatment for patients with LA-HNC. Novel induction combinations, such as that reported in the present study, should be evaluated in combination with CCRT only in the context of clinical trials. | en |
heal.access | campus | - |
heal.fullTextAvailability | TRUE | - |
heal.identifier.primary | Doi 10.1385/Mo:22:3:269 | - |
heal.identifier.secondary | <Go to ISI>://000231533600007 | - |
heal.identifier.secondary | http://link.springer.com/content/pdf/10.1385%2FMO%3A22%3A3%3A269.pdf | - |
heal.journalName | Medical Oncology | en |
heal.journalType | peer reviewed | - |
heal.language | en | - |
heal.publicationDate | 2005 | - |
heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών και Τεχνολογιών. Τμήμα Βιολογικών Εφαρμογών και Τεχνολογιών | el |
heal.type | journalArticle | - |
heal.type.el | Άρθρο Περιοδικού | el |
heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: